期刊
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
卷 18, 期 8, 页码 3421-3434出版社
IVYSPRING INT PUBL
DOI: 10.7150/ijbs.73504
关键词
HMGB1; breast cancer; autophagy; immunogenic cell death; therapy
资金
- National Key Research and Development Program of China (Stem Cell and Translational Research) [2020YFA0112300]
- National Natural Science Foundation of China [81930075, 81772799]
- Program for Outstanding Medical Academic Leader in Shanghai [2019LJ04]
- Program of Shanghai Academic/Technology Research Leader [20XD1400700]
This review summarizes the clinical value of HMGB1 in diagnosis and therapy of breast cancer, as well as its functions and mechanisms in regulating breast cancer. It discusses the strategies of chemotherapy, radiotherapy, immunotherapy, and combination therapies by targeting HMGB1, and emphasizes the importance of HMGB1 as a therapeutic target in breast cancer treatment.
HMGB1 is a member of highly conserved high mobility group protein superfamily with intracellular and extracellular distribution. Abnormal HMGB1 levels are frequently manifested in various malignant diseases, including breast cancer. Numerous studies have revealed the clinical value of HMGB1 in the diagnosis and therapy of breast cancer. However, the dual function of pro- and anti-tumor makes HMGB1 in cancer progression requires more profound understanding. This review summarizes the functions and mechanisms of HMGB1 on regulating breast cancer, including autophagy, immunogenic cell death, and interaction with the tumor microenvironment. These functions determine the strategies for the development of chemotherapy, radiotherapy, immunotherapy and combination therapies by targeting HMGB1 in breast cancer. Defining the mechanisms of HMGB1 on regulating breast cancer development and progression will facilitate the application of HMGB1 as a therapeutic target for breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据